Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results-March 2024-www.financetom.com

Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results

Jun 5, 2024 2:32 PM

05:04 PM EDT, 06/05/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Wednesday that VTX3232 effectively reduced body weight and food intake during two preclinical diet-induced obesity mouse model studies.

The results show that the drug decreased liver steatosis and triglycerides, and also had greater benefits in combination with semaglutide, according to the company.

The company said it plans to start a phase 2a study in patients with obesity and other cardiovascular risk factors during H2.

Company shares were down nearly 4% in recent after-hours activity.

Price: 5.08, Change: -0.20, Percent Change: -3.79

Previous page： Form 8.3 - IDOX LN Next page： Form 8.3 - JUST GROUP PLC

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Form 8.3 - IDOX LN

Oct 31, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

Form 8.3 - JUST GROUP PLC

Oct 31, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Form 8.3 - SPECTRIS PLC

Oct 31, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Form 8.3 - Greencore Group plc

Oct 31, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...